Clicky

Longboard Pharmaceuticals, Inc.(LBPH)

Description: Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.


Keywords: Biopharmaceutical Biology Neuroscience Psychiatry Epilepsy Neurology Amyotrophic Lateral Sclerosis Nervous System Neurophysiology Neurological Diseases Clinical Trial Product

Home Page: www.longboardpharma.com

LBPH Technical Analysis

4275 Executive Square
La Jolla, CA 92037
United States
Phone: 619 592 9775


Officers

Name Title
Mr. Kevin R. Lind Pres, CEO, Sec. & Director
Ms. Brandi L. Roberts CPA, M.B.A. Chief Financial Officer
Mr. Chadwick J. Orevillo MPH VP & Head of Operations
Megan E. Knight Head of Investor Relations
Mr. Steven W. Spector J.D. Head of Bus. Devel. & Gen. Counsel
Dr. Anne M. Danks VP & Head of Preclinical Devel.
Dr. Jodi Parsons VP & Head of Regulatory Affairs
Dr. Randall E. Kaye M.D. Chief Medical Officer
Gus Cardenas VP & Head of Quality Assurance
Dr. Marco Peters Ph.D. VP & Head of Translational Science

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.8508
Price-to-Sales TTM: 0
IPO Date: 2021-03-12
Fiscal Year End: December
Full Time Employees: 21
Back to stocks